Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: Farmland who wrote (46198)	5/22/2018 11:38:48 AM
From: Fitzhughlaw	8 Recommendations Recommended By bobbseytwins2001 btlbail1 corndog dorightbythem erippetoe and 3 more members Read Replies (3) \| Respond to of 63277

"Obvious flaws" to be sure (that's not directed at you, and thanks for posting the link, because there was indeed some valuable content there). Note that the article is dated today, and here's an excerpt discussing the tawdry history of IMMU and SGEN: "The deal’s termination lumbered Immunomedics with the cost of developing sacituzumab, and the project’s timeline has slipped – filing had been pushed back from late 2017 to early 2018, but has still not been submitted. Nevertheless, the market has reacted well, with Immunomedics stock almost tripling since May 2017; the shares rose 8% on the Asco abstract release last week." Yet another "expert" opinion by an author who apparently does not even think to use GOOGLE before publishing.....